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Background: We have reported that anti-phosphorylcholine (anti-PC) IgM is a protection marker for
human cardiovascular disease (CVD) and atherosclerosis. We here investigate the anti-PC autoanti-
bodies in a well-deﬁned cohort with regard to idiotype, atherosclerosis progression and mechanisms
for its protective action.
Methods: Serum levels and binding speciﬁcities of different anti-PC isotypes were determined in 226
hypertensive individuals enrolled in European Lacidipine Study on Atherosclerosis using ELISA. The
mean of the maximum Intima-Media Thicknesses (IMT) in the far walls of common carotids and
bifurcations was assessed at the time of inclusion, and four years afterwards. Apoptosis in immune cells
was induced with lysophosphatidylcholine (LPC) and quantiﬁed using the MTT-assay.
Results: Anti-PC IgM, IgA and IgG1 (but not IgG2) was negatively associated with IMT-progression.
Combining anti-PC IgM with data on antibodies against oxidized- and malondialdehyde-modiﬁed LDL
further strengthened this association. At very high levels, anti-PC IgM exhibited a striking negative
association with atherosclerosis progression (OR 0.05; CI 0.006–0.40). Analysis of serum samples taken
four years apart in study participants afﬁrmed the stability of anti-PC IgM titers over time. Examination
of ﬁne speciﬁcities revealed that the protective isotypes (IgM, IgA and IgG1) are of the Group I idiotype
whereas the non-protective IgG2 subclass was Group II. Anti-PC IgM inhibited LPC-induced cell death of
immune cells.
Conclusion: Group I anti-PC antibodies, particularly of the IgM class, are independent protection
markers for atherosclerosis progression. One potential mechanism of action is inhibition of LPC-induced
cell cytotoxicity.
& 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Atherosclerosis, the major underlying cause of cardiovascular
disease (CVD), is a chronic low grade inﬂammation in the artery
wall [1] characterized by the accumulation of modiﬁed lipopro-
teins, dead cells and an abundance of activated immune cells that
produce pro-inﬂammatory cytokines [2].
Modiﬁed forms of low density lipoprotein (LDL), such as
malondialdehyde modiﬁed LDL (MDA-LDL) and oxidized LDL
(oxLDL) have been linked to vascular inﬂammation and athero-
sclerosis in numerous publications utilizing a wide range of
research methodologies including [3–5].þ468300619.
nd).
Y-NC-ND license.Many of the biological effects of oxLDL are exerted through
platelet activating factor (PAF)-like lipids and lysophosphatidyl-
choline (LPC) [6,7]. Both agents are generated in the oxidation of
the omnipresent phospholipid, phosphatidylcholine, which is
abundant in LDL and plasma membranes [8,9]. This group of
pro-inﬂammatory/cytotoxic compounds generated in the oxida-
tion of LDL exhibits the phosphorylcholine (PC) epitope and PC is
one of the key epitopes found on oxLDL but not native LDL
[10,11]. It is noteworthy that, two out of three monoclonal
antibodies (E06 and DLH3) commonly used in assays to quantify
serum oxLDL levels, target the PC-moity [12]. With the patholo-
gical character of oxLDL and its related oxidized lipids in mind,
beneﬁcial effects of anti-PC antibodies have been reported, both
in vitro [10,13–15] and in vivo [16–18].
Most humans have a substantial immune response to PC and
natural PC-speciﬁc antibodies (anti-PC) have been reported to
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tion of anti-PC antibodies in serum is generally subdivided into
two idiotypes, Group I and II, based on their afﬁnity for two
haptens [20]. Group I antibodies binds both phosphorycholine
(PC) and p-nitrophenyl phosphorylcholine (NPPC) whereas Group
II antibodies require the phenyl group of NPPC in order to bind
[20]. Although this distinction has been known for a long time,
the differing roles of these two anti-PC idiotypes have not been
studied in the context of health and disease.
We have had a long interest in studying anti-PC antibodies
with focus on anti-inﬂammation in atherosclerosis. After devel-
oping a standardized protocol for measuring anti-PC IgM, we have
analyzed serum samples from several large CVD-cohorts in
Sweden. The ﬁndings have consistently been that low levels of
anti-PC IgM are associated with CVD and that high levels are
correlated with reduced rate of atherosclerosis progression
[14,21–24].
The European Lacidipine Study on Atherosclerosis (ELSA) is a
4-year prospective study on hypertension treatment in relation to
development of atherosclerosis in the carotid artery [25]. From
this cohort, we have previously determined that high levels of
anti-MDA-LDL, anti-OxLDL and anti-PC IgM (but not IgG) are
protection factors for atherosclerosis development [21]. In the
present study we explore the roles of anti-PC IgG1, IgG2 and IgA,
different antibody idiotypes as well as the long term stability of
anti-PC IgM levels. We have also studied combinations of anti-PC
with anti-MDA-LDL or anti-oxLDL.2. Methods
2.1. Subjects and acquisition of baseline data
Serum samples were obtained prior to enrollment and again
at follow-up from 226 individuals with established hyperten-
sion (diastolic pressure 495 mm Hg) who participated in the
Swedish component of the European Lacidipine Study on
Atherosclerosis (ELSA). During the admission process, informa-
tion on age, gender, blood pressure, weight, height, smoking
habits and previous medical history were recorded along with
laboratory values of different parameters including creatinine,
fasting glucose, total cholesterol, high-density lipoprotein
(HDL) cholesterol and triglycerides. For detailed information
on ELSA, please refer to the original article [25]. The study was
approved by the Ethics Committee of the Karolinska Hospital
and was conducted in accordance with the Helsinki Declara-
tion. All subjects gave informed consent.
2.2. Carotid ultrasound
The mean of the maximum Intima-Media Thicknesses (IMT) in
the far walls of common carotids and bifurcations (CBMmax)
was determined by B-mode ultrasonography at the time of
inclusion, and 4 years afterwards. All scans were performed with
the Biosound 200 II device (All Imaging Systems inc., Irvine
CA, USA) and read at the Ultrasound Coordinating Center with
quality assurance accomplished as reported. The levels of the
different anti-PC antibody classes/subclasses at enrollment were
evaluated with respect to increase or decrease in IMT at the
4-year follow up.
2.3. Puriﬁcation of serum anti-PC IgG and IgM
Pooled human IgG (Baxter, Deerﬁeld IL, USA) and IgM (Sigma
Aldrich, St. Louis MO, USA) was passed over PC-Sepharose
columns (Biosearch technologies, Novato CA, USA). The columnswere then washed with Phosphate Buffered Saline (PBS) pH
7.4 with Tween20 to remove non-bound immunoglobulins. These
non-anti-PC antibodies were collected to be used as control
antibodies (ﬂowthrough immunoglobulins) in later experiments.
The bound PC-speciﬁc antibodies were then eluted with 0.01 M
acetic acid and concentrated/buffer exchanged to PBS pH 7.4 using
Centricon Plus-70 centrifugation ﬁlter units (Millipore, Billerica
MA, USA).
2.4. Determination of antibody levels and binding speciﬁcities
Detection of IgM anti-PC antibodies was performed with an
enzyme linked immunoassay (ELISA) using Athera CVDeﬁneTM kit
(Athera Biotechnologies AB, Stockholm, Sweden). The kit is based
on PC covalently linked to bovine serum albumin (PC-BSA) coated
onto 96-well Nunc Maxisorp micro-titer plates. The assay was
carried out in accordance with the manufacturer’s recommenda-
tions. All readings of results were performed on ELISA Multiscan
Plus spectrophotometer (Molecular Devices Emax, San Francisco).
For the determinations of anti-PC IgA, IgG1 and IgG2 titers,
we utilized the pre-coated CVDeﬁne plate combined with isotype-
speciﬁc secondary antibodies purchased from Sigma Aldrich (goat
anti-human IgA) and Invitrogen (monoclonal mouse anti-human
IgG1/IgG2).
The binding speciﬁcity of human anti-PC IgG1, IgG2, IgM and
IgA were determined in a competitive ELISA with p-nitrophenyl-
phosphorylcholine (NPPC) hapten or phosphorylcholine (PC)
hapten in accordance with previously published work [20].
Brieﬂy, hapten was mixed with pooled IgA or afﬁnity puriﬁed
anti-PC from pooled IgG/IgM and incubated on CVDeﬁne plates.
Antibody of each isotype was then detected with the above-
mentioned class/subclass speciﬁc secondary antibodies.
Anti-oxLDL and anti-MDA-LDL were analyzed by ELISA as
previously described [26]. In summary, LDL was isolated from
plasma of healthy donors by sequential preparative ultra-centri-
fugation and oxidized using copper ions (oxLDL) or derivatized
with MDA (MDA-LDL). These were then coated on microplates,
which were later blocked with 20% adult bovine serum in PBS
(20% ABS-PBS). Diluted serum samples were incubated overnight
at 4 1C. The presence of speciﬁc antibodies in the serum was
detected using goat anti-human IgG ALP/anti-human IgM ALP in
combination with substraste (pNPP) and read at 405 nm.
2.5. Cell viability assay
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy coats using the standard protocol of Ficoll density gradient
centrifugation. The freshly produced PBMC were counted and
resuspended in RPMI 1640 before being seeded into 24-well
plates at a concentration of 3106 cells per ml.
L-a-Lysophosphatidylcholine (LPC) from egg yolk (Sigma) was
ﬁrst dissolved in ethanol and then further diluted in RPMI 1640 to
a working stock solution. LPC was added to the cells of each well,
either by itself, together with puriﬁed anti-PC IgM, total IgM or
ﬂowthrough IgM. After a 18 hour incubation period, cell viability
was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl-tetrazolium bromide (MTT) assay. Live cells with functioning
mitochondria metabolize MTT to formazin, which absorbs light at
570 nm. The viability of the cells in each well was thus quantiﬁed
by collecting the insoluble formazin formed in each well, dissol-
ving it in DMSO and reading the optical density (OD) at 570 nm.
2.6. Statistical analysis
Antibody levels were dichotomized at the 75th, 90th and
95th percentiles. The association between antibodies and the
R. Fiskesund et al. / Results in Immunology 2 (2012) 13–18 15progression of atherosclerosis over a 4-year period were deter-
mined by estimating increases in IMT (yes or no) using condi-
tional logistic regression analysis. Adjustments were made for
possible confounders including age, smoking habits, serum cho-
lesterol, serum triglycerides and mode of anti-hypertensive treat-
ment (lacidipine, atenolol). To distinguish the ﬁne speciﬁcities
of different anti-PC isotypes, we utilized the unpaired student
t-test. These analyses were performed using SAS 9.2 release (SAS
institute, Cary NC, USA). For all statistical analyses, a two-tailed
p-valueo0.05 was considered signiﬁcant.3. Results
3.1. Baseline characteristics
The baseline characteristics of the participants at the time of
admission into the study have been detailed elsewhere [25] and
are presented in Table 1.
3.2. Serum levels of anti-PC IgM, IgG1 and IgA could
predict IMT-progression
Measurable levels of anti-PC IgG1 and IgG2 were found in
most subjects whilst levels of IgG3 and IgG4 were generally
undetectable. Thus only anti-PC IgG1 and IgG2 were included in
the subsequent investigation.Table 1
Basic characteristics of the study group at enrollment. Results are
presented as means (S.D.) BMI, body mass index; HDL, high
density lipoprotein; LDL, low density lipoprotein.
Total (N¼226)
Age (years) 57.7 (7.8)
Sex (% males) 50
BMI (kg/m2) 26.7 (3.7)
Total cholesterol (mg/dl) 232.4 (37.8)
HDL (mg/dl) 55.6 (27.6)
LDL (mg/dl) 149.4 (37.8)
Triglycerides (mg/dl) 131.6 (58.2)
Table 2
Summary of results from regression analysis for each dichotomized antibody class
in the prediction of changes in IMT over a 4-year period adjusting for smoking,
gender, total cholesterol, plasma triglycerides, age and hypertensive treatment in
subjects with established hypertension.
Variable Odds ratio 95% CI p
Lower Upper
Above 75th percentile
anti-PC IgM 0.64 0.33 1.22 0.17
anti-PC IgG (total) 0.60 0.32 1.1 0.10
anti-PC IgG1 0.40 0.21 0.76 0.005
anti-PC IgG2 0.88 0.47 1.63 0.77
Above 90th percentile
anti-PC IgM 0.019 0.07 0.52 0.001
anti-PC IgG (total) 0.60 0.25 1.4 0.24
anti-PC IgG1 0.22 0.08 0.60 0.003
anti-PC IgG2 0.96 0.38 2.43 0.94
Above 95th percentile
anti-PC IgM 0.05 0.006 0.40 0.006
anti-PC IgG (total) 0.72 0.21 2.44 0.59
anti-PC IgG1 0.24 0.06 0.97 0.045
anti-PC IgG2 0.76 0.22 2.63 0.66
Below 25th percentile
anti-PC IgA 2.46 1.22 4.99 0.012We found no correlation between anti-PC IgG2 and IMT-
changes. However, a high level of the IgG1 subclass at baseline
was strongly predictive of no increase in IMT after four years
(Table 2).
Testing serum for anti-PC IgA showed that subjects with low
levels of anti-PC IgA had increased risk for IMT-progression. A
protective effect at high levels was not seen for anti-PC IgA
(Table 2).3.3. Fine speciﬁcity differences among the anti-PC isotypes
The ﬁne speciﬁcity proﬁles of anti-PC IgM, IgA, IgG (total), IgG1
and IgG2 were determined in pooled fractions of immunoglobu-
lins to minimize the impact of individual variation. Human anti-
PC IgM (Fig. 1a) and IgA (not shown) were found to be exclusively
Group I. The IgG fraction, however, was determined to contain
both Group I and Group II antibodies. Detailed examination with
subclass speciﬁc antibodies revealed a signiﬁcant discrepancy














Fig. 1. The idiotypes of human anti-PC IgG1, IgG2 and IgM were determined in a
competitive ELISA assay with p-nitrophenylphosphorylcholine (NPPC) hapten or
phosphorylcholine (PC) hapten. The hapten concentration was 0.001 M and all
experiments were performed in triplicate. (a) Anti-PC IgM has equal afﬁnity for PC
and NPPC. (b) Anti-PC IgG1 has afﬁnity for both PC and NPPC. (c) Anti-PC IgG2 is
only inhibited by NPPC and does not exhibit any afﬁnity for PC.
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clearly made up of Group II anti-PC antibodies (Fig. 1c).
3.4. Combining anti-PC IgM with other autoantibodies against
modiﬁed LDL improves the risk assessment
Combining data on anti-PC IgM (90th percentile) with anti-MDA-
LDL (90th percentile) or anti-oxLDL IgM (90th percentile) strength-
ened the negative association with IMT-progression, Table 3. The
combinations are stronger than each of the individual markers by
themselves. However, just using the top 5th percentile of anti-PC IgM
alone actually turns out to be an even better instrument for foresee-
ing IMT-changes, Table 2. Among the twelve study participants in the
top 5th percentile, only one had IMT-progression after four years.
For those below the 95th percentile, the incidence of IMT-progression
was 137 cases in 214 subjects.
3.5. The serum levels of anti-PC IgM and IgG1 are strongly correlated
Levels of anti-PC IgG1 and IgM are highly correlated in individuals.
Spearman’s rank correlation coefﬁcient (Srcc) between the two is 0.76
(po0.0001). Combining data on anti-PC IgM and IgG1 yields very
little in increased predictive accuracy. The two variables are almost
interchangeable and do not add any unique information to each
other. Anti-PC IgM and IgA are also somewhat associated (Srcc¼0.36)
in this group of individuals.
3.6. Anti-PC IgM inhibits LPC induced cytotoxicity
Both puriﬁed anti-PC IgM and total IgM was able to inhibit
LPC-induced cytotoxicity (po0.05) in human immune cells
(Fig. 2). The effect seen with the ﬂowthrough IgM fraction (largely
depleted of anti-PC IgM) was not signiﬁcant.Table 3
Combining anti-PC IgM (highest 10th percentile) with anti-MDA-LDL IgM or anti-
oxLDL IgM improves the predictive accuracy of IMT-changes.
Odds ratio 95% CI p
aOxLDL IgM (highest 25th percentile) 0.12 0.03–0.42 0.0011
aMDALDL (highest 25th percentile) 0.14 0.04–0.52 0.0031
aOxLDL IgM (highest10th percentile) 0.12 0.03–0.54 0.0061
MDALDL (highest 10th percentile) 0.10 0.01–0.85 0.0347
Fig. 2. LPC (16 mg/ml) was added to peripheral blood mononuclear cells. Either
alone or together with antibodies (20 mg/ml). Anti-PC IgM and total IgM (which
contains anti-PC IgM) inhibited LPC-induced cytotoxicity (po0.05) whereas
ﬂowthrough IgM, which is almost void of anti-PC does not signiﬁcantly do so.3.7. Serum levels of anti-PC IgM are stable over a four year period
The level of anti-PC IgM was measured in serum samples taken
at two time points, four years apart (admission and follow-up).
During this time period, levels of anti-PC IgM changed remarkably
little in most patients. The Spearman rank correlation coefﬁcient
between the samples taken 4 years apart was determined to be
0.92 with a p-value of less than 0.0001.4. Discussion
We here report that anti-PC IgM, IgA and IgG1 are associated
with decreased likelihood of IMT-progression in hypertensive
study subjects. This is not seen for anti-PC IgG2, which has a
different afﬁnity proﬁle.
Anti-PC research started many decades ago when products
from certain myeloma cell lines were identiﬁed as PC-reactive
[27]. These antibodies were originally thought to be directed
against certain pathogenic bacteria that display the PC-moity,
including Streptococcus pneumonie [28]. However, an increasing
body of evidence has since suggested a homeostatic function for
anti-PC besides its role in infection defense [29]. It was reported
in 2000 that oxLDL and apoptotic cells display the PC epitope [10]
and later studies have shown that anti-PC antibodies can aid in
the clearance of these pro-inﬂammatory agents and even prevent
the formation of foam cells [14]. Our group recently published an
article demonstrating that anti-PC extracted from human serum
can inhibit the pro-inﬂammatory effect of PAF whose analogs
formed through lipid oxidation are believed to be major inﬂam-
matory mediators in the atherosclerotic plaque [30]. It is possible
that these natural antibodies, which make up a sizeable portion of
the human antibody pool constitute a clearance system for aging
and/or oxidized or otherwise modiﬁed lipoproteins and dying
cells [31]. After all, it is generally known that anti-PC antibodies
belong to a set of natural antibodies produced by CD5þ B1 B-cells
of the innate immune system independent of external antigens as
demonstrated in germ free mice [10]. This ‘‘house-keeping’’
model maintains that high level of anti-PC is beneﬁcial and
insufﬁciency predisposes individuals for diseases related to
chronic inﬂammation such as atherosclerosis [10].
Anti-PC antibodies are subdivided into two populations based
on their afﬁnity for phosphorylcholine (PC) and p-nitrophenyl-
phosphorylcholine (NPPC) [20]. We have demonstrated that
human anti-PC IgM, IgA and IgG1 are Group I anti-PC antibodies
(similar to the murine T-15 clone), whereas anti-PC IgG2 is
entirely made up of Group II antibodies. Fig. 1c shows that
PC-hapten does not inhibit anti-PC IgG2, quite the contrary.
Adding PC strengthens the signal from anti-PC IgG2, possibly by
neutralizing Group I (IgG1) antibodies and thereby freeing up
space on the ELISA plate for more anti-PC IgG2 to bind, enhancing
its signal.
Patients suffering from periodontal diseases have an elevated
risk for CVD [32] even though they develop high titers of anti-PC
IgG2 [33]. This ﬁnding contradicts the ‘‘house-keeping’’ hypoth-
esis, in which high levels of anti-PC antibodies are supposed to
prevent atherosclerosis and CVD. However, our new data provides
an explanation. We have clearly demonstrated that only anti-
bodies of the Group I idiotype are associated with decreased
atherosclerosis progression. The level of anti-PC IgG2 (Group II)
was not associated with IMT-changes at all (p¼0.94). Given that
the IgG2 antibodies in general are used to counter carbohydrate
antigens [34], it is likely that anti-PC IgG2 is directed against
capsulated bacteria. Human anti-PC IgG2 has, in fact, been
implicated as a bactericidal protective factor against Haemophilus
inﬂuenza and Streptococcus pneumonie [35].
R. Fiskesund et al. / Results in Immunology 2 (2012) 13–18 17Anti-PC IgG2 was found to be non-protective in this cohort. It
is possible that this is related to the inability of the IgG2 subclass
to engage Fc-receptors and recruit complement. However, the fact
that anti-PC IgG2 has a different ﬁne speciﬁcity and is heavily
induced during infections suggests that this isotype of anti-PC
might be primarily involved in infection defense. The serum level
of anti-PC IgG2 is thus, likely determined through infections by
PC-bearing pathogens and hence unrelated to CVD.
We have previously demonstrated that anti-PC can inhibit
the formation of foam cells and neutralize the pro-inﬂammatory
effect of PAF [14,30]. In this study, we have identiﬁed an
additional mechanism through which anti-PC could confer pro-
tection against CVD and atherosclerosis, where dead cells are
abundant. Apoptosis is known to weaken advanced atherosclero-
tic plaques [36] and inhibiting LPC-induced cell death could be
very important in stabilizing plaques that might otherwise
rupture, especially considering the richness of LPC in plaques [37].
Anti-PC IgM has consistently shown signiﬁcant negative cor-
relations with CVD [14,21–24]. This study introduces two new
biomarkers, anti-PC IgG1 and IgA. Spearman rank correlation
coefﬁcients show that levels of anti-PC IgM, IgA and IgG1 are all
associated. This implies that it is only necessary to measure one
antibody class since measuring more classes would be redundant.
Given that all previous publications have been about anti-PC IgM
and the availability of a ready-to-use ELISA kit, it may be wise to
use anti-PC IgM for risk assessments. However, the role of anti-PC
IgA deserves further study due to its intricate connection with gut
immunity.
We have previously shown that high levels of anti-PC IgM,
anti-MDA-LDL and anti-oxLDL are negatively associated with IMT
progression in this cohort [21]. In the present study, we have
demonstrated that combining anti-PC IgM with anti-MDA-LDL or
anti-oxLDL yields two new composite protective parameters
which are superior to any of the three markers by themselves.
Anti-MDA-LDL like anti-PC is a natural antibody that has been
widely studied in the context of CVD [15]. The ﬁnding that the
two antibodies can act in synergy opens up exciting avenues
related to in vitro experiments as well as immunization strategies
involving induction of both anti-PC and anti-MDA-LDL. Although
combining the three different antibodies produces impressive
odds ratios (OR), the best OR is obtained by looking at the very
highest levels of anti-PC IgM alone (above the 95th percentile)
where the OR is 0.05. While the limited number of individuals in
this group urges caution, it is still a striking ﬁnding.
Long term stability is important quality for a biomarker that
makes claim to predict atherosclerosis progression and cardio-
vascular events many years in the future. A previous study
indicated that anti-PC IgM was constant over a period of many
weeks [38]. Here we have, for the ﬁrst time, shown that the levels
are steady over a four year period.
In summary, the serum levels of Group I anti-PC antibodies can
be used to predict progression of carotid IMT in patients with
hypertension. Of the different Group I isotypes, particularly anti-
PC IgM stands out as a stable biomarker candidate, which at very
high levels is associated with a striking decrease in likelihood of
atherosclerosis progression. One possible novel biological expla-
nation for this observation is that anti-PC IgM can inhibit LPC-
induced apoptosis and thus stabilize atherosclerotic plaques.Funding sources
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